One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial

Prior gestational diabetes mellitus (pGDM) is associated with increased risk of nonalcoholic fatty liver disease (NAFLD). Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has shown beneficial effects in NAFLD patients. We evaluated the effect of the GLP-1 analogue liraglutide on NAFL...

Descripción completa

Detalles Bibliográficos
Autores principales: Vedtofte, Louise, Bahne, Emilie, Foghsgaard, Signe, Bagger, Jonatan I., Andreasen, Camilla, Strandberg, Charlotte, Gørtz, Peter M., Holst, Jens J., Grønbæk, Henning, Svare, Jens A., Clausen, Tine D., Mathiesen, Elisabeth R., Damm, Peter, Gluud, Lise L., Knop, Filip K., Vilsbøll, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601647/
https://www.ncbi.nlm.nih.gov/pubmed/33036179
http://dx.doi.org/10.3390/jcm9103213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601647/
https://www.ncbi.nlm.nih.gov/pubmed/33036179
http://dx.doi.org/10.3390/jcm9103213

Ejemplares similares